These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 16816952)

  • 1. Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene.
    Tonini G; Bizzarri C; Bonfanti R; Vanelli M; Cerutti F; Faleschini E; Meschi F; Prisco F; Ciacco E; Cappa M; Torelli C; Cauvin V; Tumini S; Iafusco D; Barbetti F;
    Diabetologia; 2006 Sep; 49(9):2210-3. PubMed ID: 16816952
    [No Abstract]   [Full Text] [Related]  

  • 2. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating [corrected] mutations: evidence for improvement in insulin sensitivity.
    Malecki MT; Skupien J; Klupa T; Wanic K; Mlynarski W; Gach A; Solecka I; Sieradzki J
    Diabetes Care; 2007 Jan; 30(1):147-9. PubMed ID: 17192350
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
    Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
    Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation.
    Klupa T; Edghill EL; Nazim J; Sieradzki J; Ellard S; Hattersley AT; Malecki MT
    Diabetologia; 2005 May; 48(5):1029-31. PubMed ID: 15838686
    [No Abstract]   [Full Text] [Related]  

  • 7. Permanent neonatal diabetes mellitus caused by a novel mutation in the KCNJ11 gene.
    Doneray H; Houghton J; Tekgunduz KS; Balkir F; Caner I
    J Pediatr Endocrinol Metab; 2014 Mar; 27(3-4):367-71. PubMed ID: 24150202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
    Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
    Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DEND syndrome due to V59A mutation in KCNJ11 gene: unresponsive to sulfonylureas.
    Itoh S; Matsuoka H; Yasuda Y; Miyake N; Suzuki K; Yorifuji T; Sugihara S
    J Pediatr Endocrinol Metab; 2013; 26(1-2):143-6. PubMed ID: 23382304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene.
    Vendramini MF; Gurgel LC; Moisés RS
    Arq Bras Endocrinol Metabol; 2010 Nov; 54(8):682-4. PubMed ID: 21340152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds.
    Zhang M; Chen X; Shen S; Li T; Chen L; Hu M; Cao L; Cheng R; Zhao Z; Luo F
    J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):877-84. PubMed ID: 25781672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
    Philla KQ; Bauer AJ; Vogt KS; Greeley SA
    Diabetes Care; 2013 Dec; 36(12):e201. PubMed ID: 24265373
    [No Abstract]   [Full Text] [Related]  

  • 14. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
    Siklar Z; Ellard S; Okulu E; Berberoğlu M; Young E; Savaş Erdeve S; Mungan IA; Hacihamdioğlu B; Erdeve O; Arsan S; Oçal G
    J Pediatr Endocrinol Metab; 2011; 24(11-12):1077-80. PubMed ID: 22308870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
    Bremer AA; Ranadive S; Lustig RH
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
    Proks P; Girard C; Baevre H; Njølstad PR; Ashcroft FM
    Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
    Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
    Kim MS; Kim SY; Kim GH; Yoo HW; Lee DW; Lee DY
    J Korean Med Sci; 2007 Aug; 22(4):616-20. PubMed ID: 17728498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer from insulin to sulfonylurea treatment in a chinese patient with permanent neonatal diabetes mellitus due to a KCNJ11 R201H mutation.
    Xiao X; Wang T; Li W; Song H; Gong C; Diao C; Yu M; Yuan T; Zhang Y; Sun X; Zhang Q; Lu K; Wang H; Schmitz O; Hansen T
    Horm Metab Res; 2009 Jul; 41(7):580-2. PubMed ID: 19247925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.